Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ranmark

Roche Basel Switzerland

FDA approval for Roche diagnostic solid tumour test

Test will identify which patients could benefit from GSK immunotherapy.

Improving Health Through Integrated & Personalized Patient Care

Hicham Naim, Global Head, Integrated & Personalized Patient Care Program, Digital Advisory Board at Takeda & Founder of Curated Health, explores digital medicine & biomarkers, outcomes-based business models, Software as...

Impetus Digital

- PMLiVE

GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients

Final efficacy analysis confirms previous positive findings from interim analysis

Article:

The disparity of patient experiences with Crohn’s Disease in Europe and Japan

Research Partnership

- PMLiVE

EMA concludes GSK, Vir’s mAb can be used to treat high-risk COVID-19 patients

Recommendations can be used to support national advice prior to marketing authorisation

- PMLiVE

AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate

Datopotamab deruxtecan shows early promise in heavily pre-treated patient group

- PMLiVE

Sandoz to acquire GSK’s cephalosporin antibiotic brands for up to $500m

Sandoz, the generics division of Novartis, will pay $350m upfront for three established brands

- PMLiVE

Takeda and KSQ Therapeutics to develop immune-based cancer treatments

Collaboration will utilise KSQ’s CRISPR-screening technology

Effects of the Pandemic on Evidence Generation & Scientific Exchange

Farah Husein, Director, Evidence Generation, Canadian Centre of Excellence, at Takeda, discusses all things evidence generation, including the impact of the COVID-19 pandemic on HEOR, RWE, epidemiology, and PRO studies and...

Impetus Digital

- PMLiVE

Joint COVID-19 trial begins testing drugs from Amgen, UCB and Takeda

Trial will test therapeutic candidates in hospitalised COVID-19 patients

AstraZeneca AZ

Japan resumes AZ’s COVID-19 vaccine trial, but US study remains on hold

Trials have also resumed in the UK, India, South Africa and Brazil

- PMLiVE

GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2

Treatment could be transformative for around 260 million people living with disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links